Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671096 | 0.81 | ALDH1A1 (0.43) | SRCBRD4ALDH1A1 | |
| SCHEMBL16423639 | 0.81 | HSD17B10 (0.50) | SRCERN1BRD4ALDH1A1MAPT | |
| SCHEMBL6702064 | 0.81 | ALDH5A1 (0.50) | ALDH5A1ABATSENP1ERN1BACE1 | |
| SCHEMBL13652314 | 0.80 | ALDH1A1 (0.46) | SRCBRD4ALDH1A1MAPT | |
| SCHEMBL6246454 | 0.79 | SENP1 (0.56) | SENP1ESR1ESR2 | |
| SCHEMBL4894861 | 0.78 | ALDH5A1 (0.52) | ALDH5A1ABATBACE1ESR1ESR2 | |
| SCHEMBL2846017 | 0.77 | SENP1 (0.54) | SENP1ESR1ESR2ALDH1A1 | |
| Water SCHEMBL11499545 | 0.77 | SENP1 (0.54) | SENP1ESR1ESR2 | |
| SCHEMBL6058629 | 0.77 | ALDH5A1 (0.50) | ALDH5A1ABATSENP1ERN1ESR1 | |
| SCHEMBL2272743 | 0.77 | MAPT (0.41) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-6563008-B2 | Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast | AVENTIS PHARMA S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | disclosed |
| US-6177500-B1 | CONTAINING A P-OXYBENZOYL UNIT (A) AND A 4'-OXYBIPHENYL-4-CARBONYL UNIT (B) AND 1 TO 400 PARTS BY WEIGHT OF AN INORGANIC FILLER. | SUMITOMO CEMICAL COMPANY, LIMITED (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0757982-B1 | Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL INC (FR) | 2000-09-20 | — | — | EP | disclosed |
| US-5965763-A | Biphenyl compounds | HOECHST MARION ROUSSEL (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5827887-A | 5-ALPHA REDUCTASE INHIBITORS | ROUSSEL UCLAF (FR) | 1998-10-27 | — | — | US | disclosed |
| EP-0757982-A1 | Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1997-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | ALDH5A1 986/4885ABAT 2533/4885SENP1 3864/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | ALDH5A1 571/4885ABAT 1040/4885SENP1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.